On November 9, 2021 Alligator Bioscience AB (publ) ("Alligator" or the "Company") reported that it has prepared a prospectus (the "Prospectus") relating to the rights issue of shares of approximately SEK 257 million (the "Rights Issue"), which was resolved by the Board of Directors on 7 October 2021 and approved by the Extraordinary General Meeting held on 8 November 2021 (Press release, Alligator Bioscience, NOV 9, 2021, https://alligatorbioscience.se/en/alligator-bioscience-publishes-prospectus-in-connection-with-forthcoming-rights-issue/ [SID1234594882]). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Summary of the Rights Issue
One (1) existing share in the Company entitles to three (3) subscription rights. Two (2) subscription rights entitle to subscription of one (1) new share, i.e., a subscription ratio of 3:2.
The subscription price is SEK 2 per new share, which, assuming the Rights Issue is fully subscribed, results in the Company receiving issue proceeds of approximately SEK 257 million before deduction of transaction costs.
The Company has received subscription commitments from all members of the Company’s board and management with shareholdings in the Company, and a selection of the Company’s larger existing shareholders, including the AP4, Roxette Photo NV and Omentum S.A., amounting to approximately SEK 44 million, corresponding to approximately 17 percent of the Rights Issue. Furthermore, the Company has entered into agreements on guarantee commitments of approximately SEK 214 million, which secures the Rights Issue up to 100 percent. In addition, Öhman Fonder have expressed their intention to subscribe for their pro rata share in the Rights Issue.
For complete information on the Rights Issue, please see the published Prospectus.
Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 9 November 2021, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company’s, Aktieinvest FK AB’s and Redeye AB’s respective websites (www.alligatorbioscience.com, View Source and View Source). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on the Company’s, Aktieinvest FK AB’s, and Redeye AB’s respective websites.
Timetable for the Rights Issue
9 November 2021
First day of trading excl. preferential rights
9 November 2021
Publication of prospectus
10 November 2021
Record date
12 November – 23 November 2021
Trading in subscription rights
12 November – 26 November 2021
Subscription period
12 November 2021 – Until the Rights Issue is registered at the Swedish Companies Registration Office
Trading in paid subscription shares (Sw. "BTA")
1 December 2021
Estimated publication of outcome in the Rights Issue
Advisers
DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser to Alligator and Baker & McKenzie Advokatbyrå KB acts as legal adviser to the Joint Global Coordinators in connection with the Rights Issue. Aktieinvest FK AB acts as the issuing agent in the Rights Issue.